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Abstract
Purpose To assess whether the content of Scientific Advice
(SA) questions addressed to a national drug regulatory
agency is associated with company size. This may help to
increase understanding about the knowledge, strategic, and
regulatory gaps companies face during drug development.
Methodology A cross-sectional analysis was performed of
SA provided by the Dutch Medicines Evaluation Board
(MEB) in 2006–2008. Definition of company size was
based on ranking by total revenues (Scrip’s Pharmaceutical
Company League Tables 2008). The content of each SA
question was scored according to predefined domains
(quality, nonclinical, clinical, regulatory, and product
information), their subdomains (e.g., efficacy), and a
selection of additional content variables (e.g., endpoints,
choice of active comparator).
Results Intotal,201SAdocumentsincluding1,087questions
could be identified. Small, medium-sized, and large compa-
nies asked for SA 110 (54.7%), 40 (19.9%), and 51 (25.4%)
times, respectively. Clinical questions were asked most often
(65.9%), mainly including efficacy (33.2%) and safety
questions (24.0%). The most frequent topics were overall
efficacy and safety strategy. Small companies asked quality
and nonclinical questions more often (P<0.001) and clinical
questions less frequently than large companies (P=0.004).
Small companies asked significantly more clinical questions
about pharmacokinetics, including bioequivalence, than
medium-sized and large companies (P<0.001).
Conclusion The array of topics addressed in SA provides
an interesting outlook on what industry considers to be still
unresolved in drug development and worthwhile to discuss
with regulators. Company size is associated with the
content of SA questions. MEB advice accommodates both
innovative and noninnovative drug development.
Keywords Drug development.Scientific Advice.
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Introduction
Marketing authorization of a new medicinal product is a
critical step in giving the public access to innovative
therapies that are needed to fill current pharmaceutical
gaps and unmet medical needs. Despite the increasing
number of applications for marketing authorization in
Europe, the proportion of applications with a negative
decision remains relatively high, around 25–30%, and was
even 40% for new active substances with a resolved
outcome in 2009 [1][ 2]. There is increasing concern about
the obvious gap between the output of drug development
and registration strategies applied by companies, and EU
regulatory expectations [3, 4]. Industry response to this
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DOI 10.1007/s00228-010-0919-xdevelopment indicates that improved communication
with regulatory authorities during drug development is
needed [5]. Additional regulatory requirements in recent
years have complicated the authorization procedure and
have made innovative drug development more costly.
Furthermore, with complex biologicals, advanced therapies,
and personalized medicines becoming more important, the
need for more specific guidance in drug development has
increased [6, 7].
Before and during the marketing authorization procedure
for a medicinal product, pharmaceutical companies have
various opportunities to discuss critical issues in the drug
development process with regulators. A continuous and
ongoing regulatorydialoguebetweenpharmaceuticalindustry
and regulatory authorities has often been recommended as a
strategy to support innovative drug development in an
efficient and tailored way [3, 5, 8–10]. A relevant part of
scientific regulatory dialogue is so-called Scientific Advice
(SA), the opportunity for (early) communication between a
company and a regulatory authority on quality, nonclinical,
and various clinical aspects (e.g., study design, choice of
endpoint, indication) of drug development. In Europe an
increasing proportion of market application authorizations
are preceded by SA; 47% of all applications in 2007 received
SA and in 2008 this percentage was 56% [1].
An applicant for SA can be a pharmaceutical company
or scientists developing a product. Applicants are encouraged
toseekregulatorySAasmanytimesasnecessary,butindustry
andauthoritiesarenotobligedtoadheretotheadvicereceived
or committed to accept any result of a SA procedure [11]. In
Europe, SA can either be sought from the European
Medicines Agency (EMA) or from one or more of the
national regulatory agencies. National regulatory agencies
provide SA either as a response to national SA requests or as
an answer to European SA requests, outsourced by the EMA
Scientific Advice Working Party (SAWP) to one or two of its
member countries according to expertise. A recent study
looking at SA provided by EMA demonstrated that the level
of industry adherence to SA and company size were both
predictors of a positive outcome in a marketing authorization
procedure. The study also showed that among companies
submitting a marketing application to EMA, large companies
requested SA most frequently and were more adherent to the
advice than medium-sized and small companies [9].
Considering that adherence to SA is associated with a
positive outcome in a marketing authorization procedure
and that variability in adherence to SA exists among
companies, the question arises whether company size
matters when looking at the type of SA that pharmaceutical
companies are seeking. Answering this question may help
to learn more about the knowledge, strategic and regulatory
gaps companies face during drug development and how
these differ among the various types of enterprises.
Methods
Study design and scientific advice characteristics
A cross-sectional analysis was performed of national SA
provided by the Dutch Medicines Evaluation Board
(MEB) in the years 2006–2008. SA documents were
retrieved from the MEB SA Database. Requests for SA
that were rejected by the MEB for reasons of lack of
expertise or previously received EMA advice were
excluded. In this study, individual requests for SA were
considered, so follow-up SAs for a similar medicinal
product were included.
Products for which SA was given in the study period
were categorized according to anatomical main group of
the ATC classification [12]. In case an ATC classification
was missing, the anatomical main group was assessed
based on the intended indication of the product. Products
were also categorized as new chemical substance (NCS;
chemical substance not previously approved), generic
(a product with identical qualitative and quantitative
composition and similar pharmaceutical form as original
product), biologicals (defined as vaccines, blood and
blood components, allergenics, somatic cells, gene thera-
py, tissues, and recombinant proteins), and new applica-
tion of existing drugs (previously approved chemical
substances for which a new indication, dosage form, or
other variation was being developed, in such a way that
there was a need for additional efficacy and safety
studies).
Company size was defined as small, medium-sized, and
large, based on ranking by total revenue as reported in
Scrip’s Pharmaceutical Company League Tables 2008 [13].
Companies were defined as large if ranked 1–20, medium-
sized if ranked 21–150, and small if the company was not
on the ranking list. This definition was in line with a
previous study on SA [9]. For each SA, we evaluated
whether previous advice for the same product had been
requested at the MEB, whether parallel advice had been
sought at another national regulatory agency, or both.
Data collection: characteristics of questions
Each SA submission consisted of a variable number of
questions asked by companies. All questions in 2006, 2007,
and 2008 were collected and analyzed in a standardized
fashion. Each question, being the unit of analysis, was
scored separately according to variables at three different
levels: domains, subdomains, and content variables (Fig. 1).
At the first level, the question content was analyzed
according to the following domains: quality, nonclinical,
clinical, regulatory, and product information. Scoring more
than one domain was allowed, for example, when a clinical
158 Eur J Clin Pharmacol (2011) 67:157–164issue and a product information issue were discussed in the
same question.
Secondly, subdomains were formulated and scored for
questions in the nonclinical and clinical domains. The
subdomains of the nonclinical domain were pharmacody-
namics, pharmacokinetics, and toxicology. For the clinical
domain, subdivisions were pharmacodynamics (including
dose finding studies), pharmacokinetics (including bioequi-
valence studies), efficacy, or safety. Again, scoring more
than one subdomain was allowed.
Additionally, at the third and most detailed level, each
question was scored by a selection of content variables, e.
g., primary endpoint, choice of active comparator, trial
duration, and overall efficacy program. The content
variables were selected based on general regulatory require-
ments of the drug development process and existing EMA
regulatory guidelines. In this third step, a distinction was
made between specific and strategic questions. Strategic
questions were defined as questions in which general
feedback was asked about, e.g., the overall quality program
or the clinical efficacy program. An example of a strategic
question was: “Does the MEB agree that the results of the
clinical efficacy program will be sufficient to achieve
market approval of the product for the specific indication?”.
Specific questions were defined as being related to specific
topics of the development plan for a particular study. An
example of a specific question was: “Does the MEB agree
with the chosen primary endpoints for this indication?”.
Data analysis
Associations between the type of SA questions and company
size were assessed by Pearson’s chi-squared analysis.
P-values were calculated for each variable. Differences in
average number of questions were assessed by a one way
ANOVA test.
Results
During the study period, the MEB provided SA 214 times.
Thirteen advice documents were missing (four and nine
documents in 2006 and 2007, respectively). In total, 201
SA documents, including 1,087 questions, could be
identified. SA was provided for 187 products, with 117
companies (80 small, 21 medium-sized, and 16 large
companies) receiving SA in the study period. The general
SA characteristics are given in Table 1.
SA was most frequently given for nervous system drugs
(24.9%), but for a variety of other therapeutic areas, SAwas
provided as well. More than 60% of SA was given for
generics and new applications of existing drugs. Small,
medium-sized, and large companies requested SA 110
(54.7%), 40 (19.9%), and 51 (25.4%) times respectively.
More than 40% of the companies seeking SA had
previously received advice for the same drug at the MEB
or another national agency.
On average five questions per SA submission were
asked (Table 2). Clinical questions were asked most
frequently [716 times (65.9%)]. Within the clinical sub-
domain, efficacy and safety questions were most frequently
asked [361 (33.2%) and 261 (24.0%) times, respectively].
Small companies asked significantly fewer questions per
SA compared to medium-sized and large companies (P<
0.001). Large and medium-sized companies asked signifi-
cantly more SA questions about new chemical entities than
Fig. 1 Scoring method for SA
questions
Eur J Clin Pharmacol (2011) 67:157–164 159smallcompaniesdid(P<0.001). Small companies asked 70%
of SA questions about drug development of generics and
new applications of existing drugs. These small companies
were a diverse representation of companies, including
generic companies (20%), innovative pharmaceutical or
biotech companies (40%), and other companies mainly
consisting of medical technology companies, those working
on new applications of drugs, and consultants. Medium-sized
companies, about 85% of which were innovative pharma-
ceutical or biotechnology companies, most frequently asked
SA questions related to the development of biologicals
(P<0.001).
With regard to domain, the majority of questions asked
by companies were about clinical development issues,
while for small companies quality and nonclinical questions
were more common. One out of five SA questions was on
regulatory issues, with no difference among types of
companies. Within the clinical domain, small companies
asked significantly more often about pharmacokinetics,
including bioequivalence, than medium-sized and large
Variables Advice (n=201) (% of total no. of advice)
Year
2006 77 (38.3%)
2007 47 (23.4%)
2008 77 (38.3%)
ATC code
A: Alimentary tract and metabolism 12 (6.0%)
B: Blood and blood-forming organs 16 (8.0%)
C: Cardiovascular system 34 (16.9%)
G: Genito-urinary system and sex hormones 15 (7.5%)
J: Anti-infectives 13 (6.5%)
L: Antineoplastic and immunomodulating products 29 (14.4%)
N: Nervous system 50 (24.9%)
Other 32 (15.9%)
Product type (EMEA)
NCE 43 (21.4%)
Generic 59 (29.4%)
New application of existing drug 64 (31.8%)
Biological (including biosimilars) 34 (16.9%)
Other (General advice) 1 (0.5%)
Orphan drugs
Orphan drug 3 (1.5%)
Nonorphan drug 198 (98.5%)
Company size
Small 110 (54.7%)
Medium-sized 40 (19.9%)
Large 51 (25.4%)
Type of registration procedure
Central 48 (23.9%)
Decentral 42 (20.9%)
Mutual recognition procedure 19 (9.5%)
National 11 (5.5%)
To be decided 75 (37.3%)
Missing 6 (3.0%)
Previous/parallel advice
No previous 102 (50.7%)
At MEB 17 (8.5%)
At other agencies 62 (30.8%)
At MEB and other agencies 9 (4.5%)
Missing 11 (5.5%)
Table 1 Baseline characteristics
of SA
160 Eur J Clin Pharmacol (2011) 67:157–164companies. These companies posed efficacy questions less
often than large companies (24.4 vs. 44.8%, P<0.001). The
proportion of safety and strategic questions was not
associated with company size.
In Fig. 2, the overall top ten of most frequently
addressed topics on the most detailed third level of
variables is given, showing a strong preference for clinical
topics. Overall, the most frequently asked questions were
about overall efficacy strategy (9.6%) and safety strategy
(9.1%). In addition, strategy questions about the clinical
pharmacokinetic program were in the top ten. Indication,
primary endpoints, dosing, and study population were
examples of popular specific topics. More details of the
ten most frequently asked topics are given in Table 3.
Discussion
One of the main findings in this study was that SA provided
by a national authority is indeed different, both quantita-
tively and in terms of kind of questions, when looking at
company size. Our content analysis of SA demonstrates
that the majority of questions raised by companies,
particularly the large ones, were about clinical drug
Table 2 Company size in relation to characteristics and content of SA questions
Questions (n=1,087) Small Pharma Medium Pharma Large Pharma Total P-values
Total no. of questions (%) 431 (39.7%) 310 (28.5%) 346 (31.8%) 1,087 (100%) <0.001
Average±SD no. of questions (range) 3.9±3.2 (1–18) 7.8± 5.7 (1–27) 6.8± 3.9 (1–17) 5.4± 4.3 (1–27) <0.001
ATC code
A: Alimentary tract and metabolism 29 (6.7%) 0 (0.0%) 41 (11.8%) 70 (6.4%) <0.001
B: Blood and blood-forming organs 26 (6.0%) 66 (21.3%) 7 (2.0%) 99 (9.1%) <0.001
C: Cardiovascular system 39 (9.0%) 63 (20.3%) 69 (19.9%) 171 (15.7%) <0.001
G: Genito-urinary system and sex hormones 6 (1.4%) 48 (15.5%) 60 (17.3%) 114 (10.5%) <0.001
J: Anti-infectives 40 (9.3%) 15 (4.8%) 8 (2.3%) 63 (5.8%) <0.001
L: Antineoplastic and immunomodulating products 58 (13.5%) 30 (9.7%) 75 (21.7%) 163 (15.0%) <0.001
N: Nervous system 114 (26.5%) 80 (25.9%) 58 (16.8%) 252 (23.2%) 0.003
Other 119 (27.6%) 8 (2.6%) 28 (8.1%) 155 (14.2%) <0.001
Product type (EMEA)
NCE 47 (10.9%) 89 (28.7%) 173 (50.0%) 309 (28.4%) <0.001
Generic 125 (29.0%) 17 (5.5%) 31 (9.0%) 173 (15.9%) <0.001
New application of existing drug 178 (41.2%) 106 (34.2%) 101 (29.2%) 385 (35.4%) 0.002
Biological (incl. biosimilars) 80 (18.6%) 98 (31.6%) 41 (11.8%) 219 (20.1%) <0.001
Other (general advice) 1 (0.2%) 0 0 1 (0.1%) n.a.
Previous/parallel advice
No previous 233 (54.1%) 90 (29.0%) 98 (28.3%) 421(38.7%) <0.001
At MEB 9 (2.1%) 38 (12.3%) 64 (18.5%) 111 (10.2%) <0.001
At other agencies 161 (37.4%) 154 (49.7%) 134 (38.7%) 449 (41.3%) 0.002
At MEB and other agencies 6 (1.4%) 11 (3.5%) 32 (9.2%) 49 (4.5%) <0.001
Missing 22 (5.1%) 17 (5.5%) 18 (5.2%) 57 (5.2%) 0.973
Domain
Quality 43 (10.0%) 26 (8.4%) 5 (1.4%) 74 (6.8%) <0.001
Nonclinical 69 (16.0%) 22 (7.1%) 19 (5.5%) 110 (10.1%) <0.001
Clinical 272 (63.1%) 192 (61.9%) 252 (72.8%) 716 (65.9%) 0.004
Regulatory 86 (20.0%) 59 (19.0%) 60 (17.3%) 205 (18.9%) 0.649
Product information 11(2.6%) 22 (7.1%) 22 (6.4%) 55 (5.1%) 0.009
Clinical subdomain
Pharmacodynamics (incl. dose finding) 26 (6.0%) 13 (4.2%) 27 (7.8%) 66 (6.1%) 0.154
Pharmacokinetics (incl. bioequivalence) 123 (28.5%) 30 (9.7%) 41 (11.9%) 194 (17.8%) <0.001
Efficacy 105 (24.4%) 101 (32.6%) 155 (44.8%) 361 (33.2%) <0.001
Safety 97 (22.5%) 78 (25.2%) 86 (24.9%) 261 (24.0%) 0.639
Type of questions
Strategic questions 93 (21.6%) 64 (20.6%) 65 (18.8%) 222 (20.4%) 0.627
Eur J Clin Pharmacol (2011) 67:157–164 161development. Small companies gave more attention to
quality and nonclinical issues than large companies.
The array of topics addressed in SA provides an interesting
outlook, given all the limitations caused by strategic behavior
ofcompaniesandselectiveacceptanceofSAbyregulators,on
what industry considers to be still unresolved in drug
development and worthwhile to discuss with regulators.
Regnstrom et al. emphasized the importance of adherence
to SA for a successful marketing approval [9]. The question
arises whether our findings of companies’ priorities in drug
development are in line with the most often occurring major
objections or factors for approval failure. A 2002 study with
EMA data found that major objections raised by regulators in
the marketing authorization procedure were lack of adequate
randomized controlled trials to prove clinical efficacy and the
occurrence of unresolved safety issues [3]. The EMA
reported in 2008 that critical issues related to study design
(39%), patient population (35%), endpoint (35%), and the
magnitude of an effect (48%) were important drivers of a
negative application [1]. In a 2010 study with FDA data on
orphan drugs, Heemstra et al. found that failing to achieve
primary endpoints and failing to describe the target popula-
tion were related to nonapproval [10]. Our study also showed
that topics such as study design, endpoints, study population,
and special safety issues were all among the top ten most
frequently addressed issues in SA.
Quality documentation is a particular bottleneck for small
and medium-sized enterprises (SMEs). The EMA SME office
reported that quality documentation caused 41% of the major
objections in application procedures of SMEs in 2008 [14].
Our results demonstrated that SMEs asked significantly more
often about quality issues than large companies did, with the
latter hardly discussing any quality issues. This implies that
SMEs lack knowledge regarding quality documentation or
lack capacity to comply with the requirements.
Some limitations of this study need to be discussed.
Firstly, the scoring method of the SA, although highly
standardized, may be susceptible to some subjectivity. In
order to minimize this, we scored the questions according
to strict definitions of content variables. These variables
were derived from scientific regulatory documents and
guidelines. Secondly, our definition of company size differs
from the official EU definition of SMEs. According to the
official SME definition, only 15 of 201 SA requests would
have been classified as an SME request. This would create
a group of “large companies” that was too heterogeneous to
draw any conclusions about. Therefore, we based the SME
definition on ranking by total revenue as reported in Scrip’s
Pharmaceutical Company League Tables 2008, which was
in line with a previous study on SA with EMA data [9].
Another limitation of our study is that we did not
investigate the companies’ reasons for seeking SA. These
reasons may range from a real interest in the answers to
expected positive effects on the regulatory process (and
outcome) by the applicants owing to dialogue and align-
ment with regulators in general.
It should be noted that company budgets may drive the
decision to ask SA. However, during a significant part of the
research period, the MEB provided SA free of charge. In
addition, thecosts that were introduced laterwereverylimited,
ranging from 3500 to 8000 euro per SA. Therefore we believe
it is unlikely that the costs of SA have influenced our results,
and we do not consider this a limitation of our study.
The fact that some SA requests at the MEB were rejected
may raise the question whether results of this study are
representative for national SA provided by other regulatory
agencies. Advice requests were rejected when advice had
been obtained from EMA, in cases where the complexity
was expected to be better dealt with at the EMA level, or
when the product indication was outside the scope of the
expertise of the MEB. Therefore the array of clinical areas
represented in this study is also a reflection of national
MEB expertise. Despite national expertise in, for example,
central nervous system and cardiovascular products, the
MEB gave SA about drug development in a broad range of
therapeuticareas(Table1). Similar broad ranges are expected
Top 10 Most Frequently addressed Topics (N=1087) 
0 20 40 60 80 100 120
Special Safety Issues
Validity of Measurement Method
PK strategy
Study Population
Dosing
Study Design
Efficacy Primary Endpoints
Indication
Overall Safety Strategy
Overall Efficacy strategy
Frequency
Small Medium-sized Large
Fig. 2 Top ten most frequently
addressed topics according to
size of firm
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well. In addition, when comparing the Dutch national SA
with other national SA, the top ten most frequently addressed
topics will probably not be influenced by differences in
expertise because the topics are related to drug development
in general. Therefore, we think our results give a well-
balanced overview of issues in drug development.
Regulatory dialogue about challenging issues at the
critical edge of drug development is seen as a key success
factor for bringing new medicinal products with a positive
benefit-risk to the patient. An EMA brainstorm session held
with regulators and pharmaceutical industry representatives
in 2007 made clear that a special need exists for dialogue
about new high-risk advanced therapies and technologies
Table 3 The top ten most frequently addressed topics and example questions
Topic Definition Question example
Overall efficacy strategy Questions related to the overall clinical
study program in order to prove efficacy
of a drug
Does the MEB think the proposed efficacy
program is appropriate for a marketing
authorization?
Overall safety strategy Questions related to the overall clinical
study program in order to prove safety
of a drug
Does the MEB think the proposed safety
program is appropriate for a marketing
authorization?
Indication Questions related to the definition/wording
of indication and the appropriateness of
the suggested indication
Does the Agency agree that “Treatment of
symptoms associated with interstitial cystitis/
painful bladder syndrome including bladder
pain, urinary urgency, and frequency” is a
registrable indication?
Primary efficacy endpoints Questions related to the appropriateness of
the primary endpoint selected to prove
efficacy of a drug
Does MEB agree that the primary endpoint of
overall survival supported by the secondary
endpoints of PFS, tumour response rate, and
duration of response is appropriate to support
registration of drug X as a first line in
advanced non-small cell lung cancer?
Study design Questions related to the multiple
methodological issues of a specific
randomized clinical study
The recently initiated Phase II-III clinical trial
has the following characteristics: [...] Is this
trial design acceptable for definitive confir
mation of the clinical benefit and of an
acceptable safety profile of drug X?
Dosing Questions related to the appropriateness
of the doses chosen for a clinical study
The scheme for the individual dosing is a
10 mg/kg loading dose followed by a
5 mg/kg maintenance dose.
The company is considering increasing the
maintenance dose if no adverse effects are
seen. Does the MEB agree to the proposed
dosing regimen?
Study population Questions related to the appropriateness
of the inclusion and exclusion criteria
used for patient selection in a study
Does the Agency concur with the definition of
the patient population to be studied in the
Phase 3 randomized trial to support regular
approval of their respective proposed
indications?
Pharmacokinetics strategy Questions related to the appropriateness
of the complete clinical pharmacokinetics
study program
Does the MEB agree with the proposed
clinical pharmacokinetic program?
Validity of measurement method Questions related to the application of
specific measurement methods
(e.g., symptom scores) to assess
clinical endpoints
The MD Anderson Symptom Inventory
(MDASI) will be used in the randomized
Phase 3 study to measure the patient-reported
outcomes of symptom severity and interference
(SSI). Does the Agency concur with the use
of the MDASI instrument?
Special safety issues Questions related to the investigation of
specific safety issues at the
organ-system level
Are there any specific aspects of safety you
would like us to pay special attention to?
Does the agency concur with the company’s
proposal to perform only ECGs in the proposed
pivotal studies, given the absence of a QTc
prolongation effect in a thorough QT study?
Eur J Clin Pharmacol (2011) 67:157–164 163and for new scientific approaches in targeted drug devel-
opment, such as validation of biomarkers, choice of study
endpoints, or better methods to identify treatment responders.
In addition, the use of more flexible and adaptive study
designs was raised as a key issue to be discussed in a dialogue
with regulators [5] .A c c o r d i n gt ot h eE M A ,m a n yS M E si n
particularareactiveinthedevelopmentofthehighlyinnovative
advanced therapy medicinal products (ATMPs) [14]. SA
related to such high-risk advanced therapies and technologies
are channeled to the EMA. In contrast, other small companies
asked MEB advice most frequently about generic applica-
tions, bioequivalence, and new application of existing drugs.
One may argue that answers to these SA questions could also
be found in regulatory guidelines. The need for such advice
may be partly attributable to lack of experience in drug
development or lack of clarity in existing guidelines.
The role of scientific advice also has bearing on the way
companies formulate their questions. For all types of
companies about 20% of all questions asked were “strategic.”
Further research should assess whether companies benefit
more from asking specific or strategic questions. Also, in
further research national SA could be compared to European
SA to assess whether strategic questions are asked on both
levels and to evaluate commonalities and differences in the
roles of European and national SA. Moreover, a better
understanding of the level of complexity of SA questions
would give deeper insight into the issues addressed. This
would also enable further research on how complexity drives
market authorization holders’ behavior when it comes to SA.
In conclusion, SA as provided by a regulatory authority
provides a detailed outlook of unresolved issues in drug
development. This picture is a function of industry presence
in a certain country, of the expertise at the national regulatory
authority, but also of critical issues at the edge of regulatory
decision making. Indeed, there is variability in how different
companies deal with this. The results of this study show that
company size is associated with the content of SA questions
and that national SA accommodates both innovative and
noninnovative drug development. Clinical pharmacology
topics are at the top of issues discussed in SA, a finding
that asks for more analysis on how industry, regulatory, and
academic clinical pharmacologists can fruitfully interact and
align in order to stimulate drug innovation.
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